Treating severe malaria. by Whitty, Christopher JM et al.
Whitty, CJ; Ansah, E; Reyburn, H (2005) Treating severe malaria.
BMJ, 330 (7487). pp. 317-8. ISSN 1468-5833 DOI: 10.1136/bmj.330.7487.317
Downloaded from: http://researchonline.lshtm.ac.uk/13892/
DOI: 10.1136/bmj.330.7487.317
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Treating severe malaria
Rectal artemether may be as good as intravenous quinine
Every year over a million children die of malariain Africa. In many settings, especially rural ones,most fatalities due to malaria occur outside hos-
pital, although a substantial proportion of these
children will have made contact with some level of
healthcare in their final illness.1 Of those who arrive at
hospital, many are moribund and up to half of malaria
deaths in hospitals occur within 24 hours of
admission.2 Buying time by being able to start effective
treatment for those with severe malaria in the commu-
nity therefore has the potential to save many lives.
Conventional treatment for severe malaria in Africa is
intravenous or intramuscular quinine. Providing
parenteral treatment with quinine in the community is
usually impractical and potentially hazardous. Even in
hospitals, staff are often overstretched and have some
difficulty managing intravenous quinine safely.
In this issue Aceng et al report a randomised trial of
intravenous quinine compared with rectal artemether in
cerebral malaria.3 They found that the effects of
intravenous quinine and rectal artemether were compa-
rable, both in terms of efficacy and time to recover. The
rectal artemether group had a non-significant survival
advantage. These are encouraging results. As Aceng et al
acknowledge, a single trial of this size cannot alone be the
basis for policy change. The current study would only be
able to detect a relatively large mortality difference. The
mortality in the quinine group was also on the high side
compared with some other studies. With these caveats,
taken with a similarly sized recently reported trial of
rectal artesunate compared with quinine and descriptive
studies of artemisinin suppositories, rectal artemisinins,
especially if given in the periphery, might be one safe
and effective way to reduce the risk of children dying
before reaching hospital.4–6 Rectal quinine could poten-
tially be used in a similar way. A Cochrane review found
no clear evidence of difference in outcome between
rectal and parenteral quinine, although it noted that
most trials are small and confidence intervals around
outcomes in the meta-analysis are wide.7
Use of an artemisinin suppository rather than
nothing for cases of suspected severe malaria as they
are referred to hospital seems to be justified, and
further convincing evidence of effectiveness will prob-
ably not become available as few would consider it
ethical on current evidence to compare this to placebo.
Community health workers and traditional healers can
be trained to recognise symptoms of cerebral malaria
and to administer suppositories. It would be possible to
incorporate rectal antimalarial treatment while sick
children are being transported to hospital into existing
initiatives such as the “Integrated Management of
Childhood Illness,”8 although the cost effectiveness of
this approach would need to be assessed.
That treatment in the community with an artemisi-
nin suppository for presumed severe malaria could
reduce mortality is encouraging, but it is not without
potential hazards. Its use might reduce still further the
chances of clinicians considering alternative diagnoses.
Doctors already tend to treat almost all severe febrile
disease as malaria despite evidence that many of those
who go on to die have bacterial disease.9 10 Many patients
who are referred to hospital fail to arrive because of the
multiple barriers to poor people accessing care, and the
fact that their guardians believe that they have been
treated might exacerbate that situation.11 Artemisinin
drugs should always be given with a second antimalarial,
either in combination or sequentially. If treating patients
with an artemisinin suppository without subsequently
giving a second drug became common it could increase
the risk resistance to artemisinin. These worries should
not, however, detract from the fact that providing effec-
tive antimalarial treatment close to home to reduce
delay has the potential to save many lives, and that
artemisinin suppositories seem effective and can be
used in severely ill patients in whom oral treatment is
impossible and parenteral treatment impractical.
Whether artemisinins given by any route should be
replacing quinine as the initial treatment of choice for
severe malaria in Africa remains an open question. Lit-
tle convincing evidence exists either way in African
children.12 On current evidence the difference in mor-
tality between them, if it exists, is not likely to be large
and probably only multicentre trials will have the
power to answer this. The study by Aceng et al does,
however, suggest that rectal artemether should be con-
sidered as an alternative to quinine for such trials in a
setting where healthcare workers are already over-
whelmed, as its ease of use may lead to initial treatment
being given more quickly.13
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Total hip replacement and NICE
New guidelines need to address several areas of uncertainty
Around 150-200 different hip prostheses areavailable for use. Some require cementfixation, some are cementless, and each
consists of an acetabular and a femoral component.
The evolution of hip replacement led to alterations in
design and materials, some of which proved disastrous
(the 3M Capital implant is the best known failure).1
Guidelines for the selection of implants for hip
replacement were introduced in the United Kingdom
by the National Institute for Clinical Excellence (NICE)
in 2000.2 Knowledge of the NICE guidelines is limited
among both patients and clinicians, and a noteworthy
number of surgeons in the United Kingdom are
perhaps using prostheses that are not specified as suit-
able.3 Although guidelines do not suspend individual
clinical autonomy, many surgeons are left in a
quandary as to whether they are open to litigation.
The NICE guidelines set a rate of revision for failure
of 10% or less for a given prosthesis at 10 years, or per-
formance compatible with that benchmark at three
years. Prostheses unable to satisfy these requirements
should be the subject of formal research or observa-
tional study if the implant is already in use.2 Concerns
have been raised that NICE guidelines may replace the
Bolam test in a court of law,4 supplanting the custom that
a doctor is innocent of negligence if he or she has acted
in accordance with a practice accepted as proper by a
reasonable body of men skilled in that particular art.5
In the United States, the Food and Drug Adminis-
tration authorises which hip prostheses may be used,
allowing a wide range. The American Academy of
Orthopaedic Surgeons says that most orthopaedic sur-
geons select the prosthesis based on the patient’s
needs, the surgeon’s own preference and experience,
and perhaps those of their colleagues or mentors
(personal communication, Murphy TB, 2004). The
academy provides a comprehensive booklet on
osteoarthritis of the hip, which incorporates design of
hip prosthesis, materials, fixation, and the outcomes
and survivorship of the various bearing surfaces.6
Kaiser Permanente, the largest non-profit healthcare
plan in the United States, does not produce specific
recommendations on the selection of prosthesis but
has set up a total joint registry in 2001.
Registries act as a valuable source of information on
individual prostheses, allowing informed decisions. The
Swedish hip arthroplasty registry was established in 1979.
Finland followed in 1980. The Danish hip registry is about
to publish its 10 year results, and the Danish national
association has informed us that, these results will
influence surgeons’ choice in the future and act as guide-
lines” (personal communication, Thomsen PB, 2004).
In Norway, the view is that the Charnley prosthesis is
the only device with good long term follow up results in
excess of 15 years, and until long term results are avail-
able, uncemented prostheses cannot be recommended
for routine use.7 In Holland and Germany, there are no
specific guidelines, and selection of prosthesis is left to
the surgeon. Representatives of both these countries
have emphasised that the cost of prostheses will play an
increasingly important part in future (personal commu-
nication, van Osterhout F, Puhl W, 2004). A joint registry
was introduced in the United Kingdom in 2003.
In our department, three implants were identified
that did not meet the NICE criteria.One was included in
amulticentre international trial. For the others, we raised
funds from charitable events and manufacturers to
appoint a research assistant and set up an observational
study. We obtained ethical approval and identified
patients from the operating theatre database and invited
them for review three years after their surgery. We
obtained hip scores and did radiological evaluations to
confirm that the components meet the three year mini-
mum benchmark recommended by NICE.
A spirit of cooperation with NICE is probably the
best way forward for doctors and law makers alike.
NICE guidelines, however, have areas of uncertainty.
These include a lack of specific information on the
acetabular component in published guidelines; lack of
clarity on hybrid variants—either in the form of
cementless and cemented technology combined, or in
relation to cup and stem from different manufacturers;
and the place of generic copies of original designs.
Moreover, NICE guidelines do not cover implants in
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